glp-1-ras Oral Small-Molecule GLP-1 Receptor Agonists: Mechanistic Insights and Emerging Therapeutic Strategies GLP-1 RAs Linked to Atypical

Common loading then steps up to 500 mcg daily

Duration of treatment in clinical trials has ranged from several weeks to several months, reflecting the chronic nature of fatty liver disease

The efficacy results were so impressive that an Independent Data Safety and Monitoring Board recommended the studys early termination

The low placental transfer could be caused by the release of Dipeptidyl peptidase IV positive syncytiotrophoblast-derived extracellular vesicles released by the human placenta which degrade GLP-1 in uterine blood (63), as well as to the high molecular weight of GLP-1 agonists (4 73 kDa)

2019 Sep 3;11(9):2073